In 2013, the U.S. Food and Drug Administration approved protein-bound paclitaxel (also known as nabPaclitaxel, sold as Abraxane) as a less toxic--but perhaps less effective--alternative to FOLFIRINOX for treating late-stage pancreatic cancer.
In 2013, the U.S. Food and Drug Administration approved protein-bound paclitaxel (also known as nab-paclitaxel, sold as Abraxane) used with gemcitabine. This regimen may be less toxic--but perhaps less effective--alternative to FOLFIRINOX for treating late-stage pancreatic cancer.